Efficacy and safety of erenumab in women with a history of menstrual migraine.

ABSTRACT: BACKGROUND:We performed a post hoc, subgroup analysis of a phase 3, randomized, double-blind, placebo-controlled study of erenumab for prevention of episodic migraine (STRIVE) to determine the efficacy and safety of erenumab in women with self-reported menstrual migraine. METHODS:Patients received placebo, erenumab 70?mg, or erenumab 140?mg subcutaneously once monthly during the 6-month double-blind treatment phase of STRIVE. Women who reported history of menstrual migraine and who were???50?years old were included in the analysis. Endpoints were change from baseline in monthly migraine days (MMD) and monthly acute migraine-specific medication days (MSMD; among patients who took acute migraine-specific medications at baseline), proportion of patients achieving ? 50% reduction from baseline in MMD, and incidence of adverse events. RESULTS:Among 814 women enrolled in STRIVE, 232 (28.5%) reported a history of menstrual migraine and were???50?years old. Of the 232 patients, 214 (92%) had a baseline MMD?>?5, suggesting a high proportion of women with attacks outside of the 5-day perimenstrual window (2?days before and 3?days after the start of menstruation). Information on "migraine days" includes (and does not discriminate between) perimenstrual and intermenstrual migraine attacks. Between-group differences from placebo over months 4-6 for erenumab 70?mg and 140?mg were?-?1.8 (P?=?0.001) and?-?2.1 (P?

SUBMITTER: Pavlovic JM 

PROVIDER: S-EPMC7398400 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature